TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03140501

Intervention type: DEVICE
Group type: OTHER
Intervention: Mobile application (app)
Description: The self-management app has 3 main features: 1) SCI-specific education modules; 2) a circle-of-care in which the users select health allies (formal and informal caregivers); and 3) a variety of tools to assist with goal identification, symptom/behaviour tracking, etc. The intervention will involve 5-6 contacts that occur over a 3-month period and ongoing use of the app. There will be 1 to 2 in-person sessions, where the principles of self-management are reviewed, self-management goals are identified, and features of the app are explained. Over the next month, there will be 2 follow-up contacts to review any questions/issues participants have. Participants can set additional goals during this time. Over the last 2 months, there will be monthly contacts to address the same issues.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile application (app)
Description: The self-management app has 3 main features: 1) SCI-specific education modules; 2) a circle-of-care in which the users select health allies (formal and informal caregivers); and 3) a variety of tools to assist with goal identification, symptom/behaviour tracking, etc. The intervention will involve 5-6 contacts that occur over a 3-month period and ongoing use of the app. There will be 1 to 2 in-person sessions, where the principles of self-management are reviewed, self-management goals are identified, and features of the app are explained. Over the next month, there will be 2 follow-up contacts to review any questions/issues participants have. Participants can set additional goals during this time. Over the last 2 months, there will be monthly contacts to address the same issues.
Study: NCT01106053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole
Description: Pramipexole tablet titrated up to a maximum dosage of 0.5 mg three times daily (1.5 mg/day).
Study: NCT03733561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY03003
Description: LY03003 (rotigotine extended release microspheres for intramuscular \[IM\] injection)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neupro 4Mg/24Hr Transdermal Patch
Description: neupro patch
Study: NCT04375072

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active tDCS paired with sham MBM
Description: Active tDCS with a constant current intensity of 2 mA will be applied for 20 minutes per session daily for 2 weeks via the Soterix 1x1 tDCS mini-CT Stimulator device with headgear and saline-soaked surface sponge electrodes. The sham MBM intervention will be delivered via a CD player that will look identical in both active and sham MBM.
Study: NCT01117701

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ureteroscopy with and without safety guidewire
Description: In study arm A - with SGW, the force measurements are made with a safety guidewire in place. In study arm B - without SGW, the force measurements are made without SGW.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ureteroscopy with and without safety guidewire
Description: In study arm A - with SGW, the force measurements are made with a safety guidewire in place. In study arm B - without SGW, the force measurements are made without SGW.
Study: NCT04375072

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tDCS paired with sham MBM
Description: For sham stimulation, the electrodes will be placed in the same positions as for active stimulation, but the stimulator will only deliver 2 mA current for 30 seconds. The sham MBM intervention will be delivered via a CD player that will look identical in both active and sham MBM.
Study: NCT03261674

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-I
Description: Cognitive Behavioral Therapy for Insomnia (CBT-I)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ABT-I
Description: Arousal-Based Therapy for Insomnia (ABT-I)
Study: NCT02167464

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Renin treatment-guided Therapeutics
Description: Patients are treated based upon their renin levels according to an approved algorithm.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Referral Hypertension specialist
Description: Patients are referred to a hypertension specialist.
Study: NCT03732118

Intervention type: DEVICE
Intervention: Eye-tracker Mobile EBT
Description: Use of the eye-tracker for the diagnosis of minimal HE by studying the characteristics of saccades and anti-saccades during a day hospitalization.

Intervention type: DEVICE
Intervention: Eye-tracker Mobile EBT
Description: Use of the eye-tracker for the diagnosis of minimal HE by studying the characteristics of saccades and anti-saccades during a day hospitalization.
Study: NCT01600222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 90100
Description: Calcipotriol 50 mcg/g (as hydrate) and betamethasone 0.5 mg/g (as dipropionate)
Study: NCT00058201

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leucovorin calcium
Description: Given IV

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: clinical observation
Description: No intervention
Study: NCT02206490

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naltrexone
Description: Randomized controlled trial of naltrexone for Gulf War Illness.
Study: NCT02167464

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Referral Hypertension specialist
Description: Patients are referred to a hypertension specialist.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aldosterone Antagonist
Description: Spironolactone 12.5 - 25mg daily
Study: NCT02573909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone intravenously
Description: Oxycodone intravenously 0,1mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone epidurally
Description: Oxycodone 0,1 mg epidurally
Study: NCT00940056

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic ablation of AF
Description: The procedure is conducted in general anaesthesia. The right chest is entered with three working ports .~After a complete cycle of ablation creating a box lesion in the left atrium, conduction block is tested. A chest tube is placed through the most caudal port and the port incisions are closed. A Reveal loop recorder is then implanted subcutaneously. The patient is extubated and transferred to postoperative care.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rate control
Description: Anti-arrhythmic protocol The control group is using a rate-control strategy. All patients keep their anti-arrhythmic/beta-blocker/digoxin medication during the entire follow-up. No attempts are made to rhythm-control the patients, unless subjective symptoms make it necessary.
Study: NCT00865709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin)
Description: Subjects will receive oral Sorafenib 400 mg twice daily (BID) continuously and intravenous (IV) mFOLFOX6 (5-FU 400 mg/m\^2 bolus and 2400 mg/m\^2 for 46-48 hrs; levo-leucovorin 200 mg/m\^2; 85 mg/m\^2 oxaliplatin) every 14 days until progressive disease (PD)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin)
Description: Subjects will receive oral matching placebo 2 tablets BID continuously and IV mFOLFOX6 (5-FU 400 mg/m\^2 bolus and 2400 mg/m\^2 for 46-48 hrs; levo-leucovorin 200 mg/m\^2; 85 mg/m\^2 oxaliplatin) every 14 days until progressive disease
Study: NCT01698996

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Packing vs No Packing

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Packing vs No Packing
Study: NCT02250560

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Replenine®-VF (High Purity Factor IX)
Study: NCT04170166

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterolateral subacromial steroid injection
Description: Applying to the anterolateral approach arm, this group will receive their subacromial steroid injection via an anterolateral approach
Study: NCT02206490

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: naltrexone
Description: Randomized controlled trial of naltrexone for Gulf War Illness.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dextromethorphan
Description: Randomized controlled trial of dextromethorphan for Gulf War Illness

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextromethorphan
Description: Randomized controlled trial of dextromethorphan for Gulf War Illness
Study: NCT03954743

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PCV-free liquid formulation of GSK's oral live attenuated HRV vaccine
Description: 2 doses administered orally at Day 1 and at Month 1 or Month 2, according to the immunization schedule for RV vaccine administration in participating countries.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Lyophilized formulation of GSK's oral live attenuated HRV vaccine
Description: 2 doses administered orally at Day 1 and at Month 1 or Month 2, according to the immunization schedule for RV vaccine administration in participating countries.
Study: NCT02693821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: gabapentin 300 mg per day, orally during 30 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 300 mg per day, orally during 30 days
Study: NCT01923805

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vitagel
Description: Vitagel
Study: NCT01726855

Intervention type: PROCEDURE
Intervention: vascularized finger dorsal fascial flap
Study: NCT02496767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirasemtiv

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirasemtiv

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirasemtiv

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tablets
Study: NCT03041844

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low Frequency, Low Intensity Ultrasound
Description: Therapeutic ultrasound (20 kHz, \<100 mW/cm2 spatial peak-temporal peak)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Applicator
Description: Sham ultrasound applicator
Study: NCT01729884

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HER-2/neu peptide vaccine
Description: Given ID
Study: NCT01424189

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL
Description: Multifocal IOL with extended secondary focal point and astigmatism correction implanted for long-term use over the lifetime of the cataract patient

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AcrySof® ReSTOR® Multifocal IOL Model SA60D3
Description: Multifocal IOL with extended secondary focal point implanted for long-term use over the lifetime of the cataract patient
Study: NCT01988948

Intervention type: OTHER
Group type: OTHER
Intervention: Various biological sampling
Study: NCT01262326

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Calorie and Carbohydrate Restriction
Description: Carbohydrate Restriction = \<20 g/d of dietary carbohydrate intake Calorie Restriction = 1200 kcal/d for women and 1500 kcal/d for men

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Calorie and Carbohydrate Restriction
Description: Carbohydrate Restriction = \<20 g/d of dietary carbohydrate intake Calorie Restriction = 1200 kcal/d for women and 1500 kcal/d for men
Study: NCT02872948

Intervention type: GENETIC
Intervention: Diagnostic

Intervention type: GENETIC
Intervention: Diagnostic
Study: NCT04573725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-142
Description: Participants received single-dose of 5, 10, 30 mg of TS-142 (oral capsule)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-142
Description: Participants received single-dose of 5, 10, 30 mg of TS-142 (oral capsule)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-142
Description: Participants received single-dose of 5, 10, 30 mg of TS-142 (oral capsule)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dose-matched Placebo to TS-142
Description: Participants received single dose-matched placebo to TS-142 (oral capsule)
Study: NCT04748016

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3D printed (3DP) bone models + CT imaging
Description: In addition to CT-MPR and CT-3DR, 3DP models will be used for surgical planning and intraoperative visualization.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CT imaging
Description: CT-MPR and CT-3DR used for surgical planning and intraoperative visualization.
Study: NCT01644201

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: PolyGlycopleX® - PGX®
Description: 15g or 20g total daily dose, 5g pre-mixed with liquid meal replacement and consumed twice daily, 5g supplement granules sprinkled on food and consumed once of twice daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Rice Flour (placebo)
Description: 15g or 20g total daily dose, 5g pre-mixed with liquid meal replacement and consumed twice daily, 5g supplement granules sprinkled on food and consumed once of twice daily
Study: NCT01949233

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan 150-300mg capsules daily for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan 150-300mg capsules daily for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline 100-200mg capsules daily for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline 100-200mg capsules daily for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline placebo capsules daily for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Doxycycline placebo capsules daily for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irbesartan placebo capsules daily for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Irbesartan placebo capsules daily for 6 months
Study: NCT04563533

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (without aluminum)
Description: Active ingredients: none Other ingredients: L-histidine: 1.55 mg, sodium chloride: 4 mg, Tween 80: 2 μg, sodium dihydrogen phosphate: 94 μg, disodium hydrogen phosphate: 173 μg.
Study: NCT01453348

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MenACWY-CRM
Description: Novartis meningococcal ACWY conjugate vaccine will be administered intramuscularly (IM) on day 1.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MenACWY-CRM
Description: Novartis meningococcal ACWY conjugate vaccine will be administered intramuscularly (IM) on day 1.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Combined inactivated hepatitis A & recombinant hepatitis B
Description: Combined inactivated hepatitis A and recombinant hepatitis B vaccine will be administered by IM on days 1, 8 \& 29 for subjects unprimed with hepatitis A and B; and a single booster injection on day 1 for primed subjects.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Combined inactivated hepatitis A & recombinant hepatitis B
Description: Combined inactivated hepatitis A and recombinant hepatitis B vaccine will be administered by IM on days 1, 8 \& 29 for subjects unprimed with hepatitis A and B; and a single booster injection on day 1 for primed subjects.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant hepatitis B vaccine
Description: Recombinant hepatitis B vaccine will be administered intramuscularly on days 8 and 29

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant hepatitis B vaccine
Description: Recombinant hepatitis B vaccine will be administered intramuscularly on days 8 and 29

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated hepatitis A vaccine
Description: Inactivated hepatitis A will be administered intramuscularly on days 8 and 29.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Inactivated hepatitis A vaccine
Description: Inactivated hepatitis A will be administered intramuscularly on days 8 and 29.
Study: NCT01673893

Intervention type: DEVICE
Intervention: ClearWay™ Rx catheter

Intervention type: DEVICE
Intervention: ClearWay™ Rx catheter
Study: NCT04821128

Intervention type: OTHER
Intervention: Radiologic and pathological review.
Description: We will analyse the pre operative scannographic and MRI (if available) images, and the post operative pathological analyses.~The scanners will be reviewed by 2 well trained clinicians (one head and neck radiologist and one head and neck surgeon).~Then we will analyse the correlation between the radiological and the pathological analysis.
Study: NCT03221101

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Home ventilator
Study: NCT03763916

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ureteric dissection
Description: clamping and cutting the round ligament, clamping and cutting the ovarian ligament with ovarian preservation, careful dissection and clamping of the broad ligament varicosities, careful dissection of the post leaflet of the broad ligament until ureter is reached, careful dissection and exposure of both ureter and proper identification of the iliac vessels
Study: NCT04170166

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Posterior subacromial steroid injection
Description: Applying to the posterior approach arm, this group will receive their subacromial steroid injection via an posterior approach
Study: NCT01589536

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: interval-rehabilitation
Description: The Patients in the intervention group receive a Stationary psychocardiological interval-rehabilitation.The Interval rehabilitation is divided into individual psychological therapy with focus of Behavior therapy and relaxation therapy.
Study: NCT03019393

Intervention type: OTHER
Group type: OTHER
Intervention: Beef
Description: 200 g beef topside which is fully cooked will be provided to participant after overnight fast. The intervention is one time only.
Study: NCT01310088

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: Treatment protocol. The Children's Obesity Clinic Department of Paediatrics Holbaek Hospital, University of Copenhagen Denmark
Study: NCT00378508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mAb hOKT3gamma1(Ala-Ala), Teplizumab
Description: This is a randomized, two-arm, double blind placebo controlled phase II trial in which 60 participants with recent-onset T1DM are randomized at a 1:1 ratio to receive Teplizumab or placebo over a 14 day treatment period. The course of Teplizumab comprises daily doses of 51 µg/m2, 103 µg/m2, 207 µg/m2, 413 µg/m2, and 10 of 826 µg/m2.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Arm
Study: NCT04482998

Intervention type: OTHER
Intervention: No intervention - retrospective study
Description: No intervention - retrospective study

Intervention type: OTHER
Intervention: No intervention - retrospective study
Description: No intervention - retrospective study

Intervention type: OTHER
Intervention: No intervention - retrospective study
Description: No intervention - retrospective study

Intervention type: OTHER
Intervention: No intervention - retrospective study
Description: No intervention - retrospective study
Study: NCT03763916

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative ureteric stenting
Description: preoperative insertion of ureteric catheters is performed by the urologist in our team just before the start of cesarean hysterectomy. Patient is positioned in lithotomy, cystoscopy \[Karl storz\] is done to identify the ureteric orifices. ureteric catheters \[Roche\] are inserted followed by the insertion of Foley's urethral catheter

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cesarean hysterectomy
Description: lateral dissection of the uterus is completed from the pelvic side wall, followed by very CAREFUL BLADDER DISSECTION. Finally clamping of the uterine vessels is done below the level of the placenta with or without complete removal of the cervix. Closure of the uterine stump is performed followed by CAREFUL HEMOSTASIS then closure of the abdomen is performed after leaving two wide bore drains

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cesarean hysterectomy
Description: lateral dissection of the uterus is completed from the pelvic side wall, followed by very CAREFUL BLADDER DISSECTION. Finally clamping of the uterine vessels is done below the level of the placenta with or without complete removal of the cervix. Closure of the uterine stump is performed followed by CAREFUL HEMOSTASIS then closure of the abdomen is performed after leaving two wide bore drains
Study: NCT02319070

Intervention type: OTHER
Intervention: Survey
Description: Recombinant antihemophilic factor VIII (FVIII) on Secondary Prophylaxis treatment scheduled according to daily routine
Study: NCT03628339

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Participant received single oral dose of 7.5 mg midazolam tablet on Day 1 of treatment period 1 and Day 11 in treatment period 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Participant received single oral dose of 7.5 mg midazolam tablet on Day 1 of treatment period 1 and Day 11 in treatment period 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tepotinib
Description: Participants received single oral dose of 500 mg tepotinib film-coated tablet from Day 1 to 11 in treatment period 2.
Study: NCT03360851

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: low-dose CT
Description: see arm/group description

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PoC-PCR
Description: see arm/group description
Study: NCT02319070

Intervention type: OTHER
Intervention: Survey
Description: Recombinant antihemophilic factor VIII (FVIII) On Demand treatment scheduled according to daily routine
Study: NCT03154463

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TAP Blocks
Description: TAP blocks were performed using ultrasound as a guide and injected on three points on trans abdominal plane using 100 mm stimuplex needle and 0.25% bupivacaine with total volume of 20 ml in each point (with total of 60 ml in three points)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: continuous epidural infusion
Description: Continuous epidural infusion was given with epidural regimen of 0.25% bupivacaine without any adjuvant